S&P Futures
4,059.50-86.75(-2.09%)Dow Futures
33,521.00-662.00(-1.94%)Nasdaq Futures
13,000.50-345.50(-2.59%)
Evofem Biosciences, Inc. (EVFM)
Chart Events
Performance Outlook
| Previous Close | 1.2400 |
| Open | 1.2552 |
| Bid | 1.2100 x 800 |
| Ask | 1.2200 x 45100 |
| Day's Range | 1.2050 - 1.3790 |
| 52 Week Range | 1.2050 - 6.8700 |
| Volume | 5,067,096 |
| Avg. Volume | 4,869,281 |
| Market Cap | 128.548M |
| Beta (5Y Monthly) | -0.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.1190 |
| Earnings Date | Aug 02, 2021 - Aug 06, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.40 |
- Benzinga
Fulcrum Therapeutics, Evofem Biosciences Drug Candidates Receive FDA Fast Track Designation
The FDA has granted Fast Track designation to Fulcrum Therapeutics Inc's (NASDAQ: FULC) losmapimod for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum is on track to report full data from the ReDUX4 Phase 2b trial at the virtual FSHD International Research Congress to be held next month. Losmapimod previously received Orphan Drug Designation for FSHD. Losmapimod is a selective p38α/β mitogen-activated protein kinase (MAPK) inhibitor exclusively in-licensed from GlaxoSmithKline plc (NYSE: GSK). Evofem Biosciences Inc's (NASDAQ: EVFM) EVO100 to prevent urogenital gonorrhea in women also received the Fast Track tag from the FDA. Phase 3 trial of EVO100 for prevention of chlamydia and gonorrhea in women is currently enrolling. The Company expects to complete enrollment by year-end 2021 and to report top-line data in mid-2022, with potential marketing application submission by the end of 2022. EVO100 previously received the FDA Fast Track designation for the prevention of chlamydia in women. It was also designated as a Qualified Infectious Disease Product for the prevention of gonorrhea in women. Price Action: FULC shares closed 0.38% lower at $10.40, while EVFM shares closed 0.81% higher at $1.25 on Wednesday. See more from BenzingaClick here for options trades from BenzingaVBI Vaccines' Three-Antigen HBV Vaccine Candidate Trial Data Published In Lancet Infectious DiseasesFDA To Hold AdCom Meeting For Expanding Use COVID-19 Vaccine In Children© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- PR Newswire
Evofem Biosciences Receives Fast Track Designation for EVO100 for Prevention of Gonorrhea in Women
Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EVO100 for the prevention of urogenital gonorrhea in women. Fast Track designation is designed to facilitate the development and expedite the review of new therapies to treat serious conditions and fill unmet medical needs.
- PR Newswire
Evofem Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Update
Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), today reported financial results for the three-month period ended March 31, 2021.
